6 Einträge gefunden

1. Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison

   1. Moreau, Philippe
   2. Hebraud, Benjamin
   3. Facon, Thierry
   4. Leleu, Xavier
   5. Hulin, Cyrille
   6. Hashim, Mahmoud
   7. Hu, Yannan

   2021 - Forschungsinformationssystem des UKE
2. Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age

   1. Mai, Elias K
   2. Miah, Kaya
   3. Bertsch, Uta
   4. Dürig, Jan
   5. Scheid, Christof
   6. Weisel, Katja C
   7. Kunz, Christina

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Long-term follow-up of subcutaneous versus intravenous bortezomib during induction therapy for newly diagnosed multiple myeloma treated within the GMMG-MM5 Phase III Trial

   1. Salwender, Hans
   2. Elmaagacli, Ahmet
   3. Merz, Maximilian
   4. Miah, Kaya
   5. Benner, Axel
   6. Haenel, Mathias
   7. Jehn, Christian

   2021 - Forschungsinformationssystem des UKE
4. Autologous stem cell transplantation in multiple myeloma patients: utilization patterns and hospital effects

   1. Jansen, Lina
   2. Merz, Maximilian
   3. Engelhardt, Monika
   4. Weisel, Katja
   5. Scheid, Christof
   6. Straka, Christian
   7. Langer, Christian

   2020 - Forschungsinformationssystem des UKE
5. Response-adapted lenalidomide maintenance in newly diagnosed myeloma:results from the phase III GMMG-MM5 trial

   1. Goldschmidt, Hartmut
   2. Mai, Elias K
   3. Dürig, Jan
   4. Scheid, Christof
   5. Weisel, Katja C
   6. Kunz, Christina
   7. Bertsch, Uta

   2020 - Forschungsinformationssystem des UKE
6. Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma

   1. Merz, Maximilian
   2. Hielscher, Thomas
   3. Mai, Elias Karl
   4. Seckinger, Anja
   5. Hose, Dirk
   6. Jauch, Anna
   7. Sauer, Sandra

   2019 - Forschungsinformationssystem des UKE - frei zugänglich